Parkinson's disease is clinically known for the loss of dopaminergic neurons in the
substantia nigra pars compacta and accumulation of intraneuronal cytoplasmic inclusions …

Phosphorylation of α-synuclein at the serine-129 site (α-syn Ser129P) is an established
pathologic hallmark of synucleinopathies and a therapeutic target. In physiologic states, only …

Lewy body disorders are heterogeneous neurological conditions defined by intracellular
inclusions composed of misshapen α-synuclein protein aggregates. Although α-synuclein …

Neurodegenerative diseases are commonly classified as proteinopathies that are defined by
the aggregation of a specific protein. Parkinson's disease (PD) and dementia with Lewy …

Misfolded α-synuclein (α-syn) is believed to contribute to neurodegeneration in Lewy body
disease (LBD) based on considerable evidence including a gene-dosage effect observed in …

α‐Synuclein (αS) is a key molecule in the pathomechanism of Parkinson's disease. Most
studies on αS to date have focused on its function in the neuronal cytosol, but its action in …

Abstract α-Synuclein proximity ligation assay (PLA) has proved a sensitive technique for
detection of non-Lewy body α-synuclein aggregate pathology. Here, we describe the MJF …

Parkinson's disease (PD) is a neurodegenerative disease characterized by the progressive
loss of dopaminergic neurons in the nigrostriatal pathway. Although the exact mechanisms …

Parkinson's disease (PD) is a neurological disorder characterized by motor dysfunction,
dopaminergic neuron loss, and alpha-synuclein (αSyn) inclusions. Many PD risk factors are …

Alpha-synuclein (αsyn) is an intrinsically disordered protein that aggregates in the brain in
several neurodegenerative diseases collectively called synucleinopathies. Phosphorylation …